
    In re IN RE BEXTRA AND CELEBREX MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION In re Bextra and Celebrex Products Liability Litigation In re Bextra Marketing and Sales Practices Litigation In re Celebrex Marketing and Sales Practices Litigation
    Nos. MDL-1699, MDL-1691, MDL-1693, MDL-1694.
    Judicial Panel on Multidistrict Litigation.
    Sept. 6, 2005.
    
      Before WM. TERRELL HODGES, Chairman, JOHN F. KEENAN, D. LOWELL JENSEN, J. FREDERICK MOTZ, ROBERT L. MILLER, Jr., KATHRYN H. YRATIL and DAVID R. HANSEN, Judges of the Panel.
    
      
       Judge Motz took no part in the decision of this matter.
    
   TRANSFER ORDER

Before the Panel are five motions, pursuant to 28 U.S.C. § 1407, in these four dockets that taken together seek centralization for coordinated or consolidated pretrial proceedings of all, or a subset of, these 31 actions, in various federal districts. The moving MDL-1691 Louisiana plaintiffs seek centralization of the Bextra and Celebrex products liability actions in the Eastern District of Louisiana, while the moving Connecticut plaintiffs seek centralization of these actions in the District of Connecticut. The moving Southern New York MDL-1693 plaintiff seeks centralization of all Bextra and Celebrex actions in the Southern District of New York. The moving MDL-1694 plaintiffs seek separate centralization of the Bextra actions and the Celebrex actions in the District of Massachusetts before different judges. The moving MDL-1699 Louisiana plaintiffs seek centralization of all Bextra and Ce-lebrex actions in the Eastern District of Louisiana. Most responding plaintiffs agree that centralization is appropriate, although some plaintiffs suggest alternative transferee districts, including the Northern District of California, the District of Delaware, the Southern District of Florida, the District of New Jersey, and the Southern District of Texas. Defendant Pfizer Inc. (Pfizer) opposes centralization of the products liability actions, but supports centralization of the marketing/sales practices actions. Pfizer suggests coordination of this latter group of actions (and of the products liability actions, if the Panel deems centralization of these actions to be appropriate) with MDL-1688-7A re Pfizer Inc. Securities, Derivative and “ERISA” Litigation in the Southern District of New York.

On the basis of the papers filed and hearing session held, the Panel finds that the actions in these four multidistrict dockets involve common questions of fact, and that Section 1407 centralization of all actions as one multidistrict docket (MDL-1699) in the Northern District of California will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. All actions focus on i) alleged increased health risks from taking Celebrex and/or Bextra, anti-inflammatory prescription medications, and ii) whether Pfizer, as the manufacturer of both medications, knew of these increased risks and failed to disclose them to the medical community and consumers and/or improperly marketed these medications to both of these groups. Centralization under Section 1407 is necessary in order to eliminate duplicative discovery, avoid inconsistent pretrial rulings, and conserve the resources of the parties, their counsel and the judiciary. Resolution of overlapping issues, concerning these similar prescription medications manufactured by the same company, will be streamlined. See In re Humana Inc. Managed Care Litigation, 2000 WL 1925080, 2000 U.S. Dist. LEXIS 15927 (Jud.Pan.Mult.Lit. Oct. 23, 2000).

Opponents of Section 1407 centralization of all actions in one multidistrict docket argue that the presence of unique questions of fact relating to each drug (Bextra and Celebrex) or to the type of claims asserted (products liability and marketing/sales practices) should produce a different result. These parties urge us, instead, to separately centralize these actions. We are unpersuaded by these arguments. Transfer under Section 1407 has the salutary effect of placing all actions before a single judge who can formulate a pretrial program that: 1) allows discovery with respect to any non-common issues to proceed concurrently with discovery on common issues, In re Smith Patent Litigation, 407 F.Supp. 1403, 1404 (Jud.Pan.Mult.Lit.1976); and 2) ensures that pretrial proceedings will be conducted in a manner leading to the just and expeditious resolution of all actions to the overall benefit of the parties. The transferee court can employ any number of pretrial techniques — such as establishing separate discovery and/or motion tracks— to efficiently manage this litigation. In any event, we leave the extent and manner of coordination or consolidation of these actions to the discretion of the transferee court. In re Mutual Funds Investment Litigation, 310 F.Supp.2d 1359 (Jud.Pan.Mult.Lit.2004). We are confident in the transferee judge’s ability to streamline pretrial proceedings in these actions, while concomitantly directing the appropriate resolution of all claims.

Given the geographic dispersal of constituent actions and potential tag-along actions, no district stands out as the geographic focal point for this nationwide docket. Thus we have searched for a transferee judge with the time and experience to steer this complex litigation on a prudent course. By centralizing this litigation in the Northern District of California before Judge Charles R. Breyer, we are assigning this litigation to a jurist experienced in complex multidistrict litigation and sitting in a district with the capacity to handle this litigation.

IT IS THEREFORE ORDERED that, pursuant to 28 U.S.C. § 1407, the actions listed on the attached Schedule A and pending outside the Northern District of California are transferred to the Northern District of California and, with the consent of that court, assigned to the Honorable Charles R. Breyer for coordinated or consolidated pretrial proceedings with the action pending there and listed on Schedule A.

IT IS FURTHER ORDERED that the actions in MDL-1691, MDL-1693 and MDL-1694 are merged into MDL-1699-Tk. re Bextra and Celebrex Marketing, Sales Practices and Products Liability Litigation.

SCHEDULE A

MDL-1699 — In re Bextra and Celebrex Marketing. Sales Practices and Products Liability Litigation

Northern District of Alabama

Darryl Blue, etc. v. Pfizer, Inc., C.A. No. 2:05-464

Martha Ann Lemond, et al. v. Merck & Co., Inc., et al., C.A. No. 7:05-691

District of Arizona

Dorothy Greaves v. Pfizer, Inc., et al., C.A. No. 2:05-647

Central District of California

John Bolwell, et al. v. Pfizer, Inc., C.A. No. 2:05-1967

Northern District of California

June Swan, et al. v. Pfizer, Inc., et al., C.A. No. 3:05-834

District of Connecticut

Kenneth Kaye, et al. v. Pfizer, Inc., C.A. No. 3:05-385

Irene Bailey, et al. v. Pfizer, Inc., et al., C.A. No. 3:05-386

District of Delaware

Ronnie L. Hatcher v. Pfizer, Inc., et al., C.A. No. 1:05-208

Northern District of Florida

Mane McConnell v. Pfizer, Inc., C.A. No. 3:05-123

Southern District of Florida

Aurora Balloveras v. Pfizer, Inc., C.A. No. 1:05-20429

Eastern District of Louisiana

Gloria Ward v. Pfizer, Inc., C.A. No. 2:04-3469

Elmer E. Creel, Sr., et al v. Pfizer, Inc., C.A. No. 2:04-3470

Carol J. Aiola v. Pfizer, Inc., C.A. No. 2:05-1207

Ronald J. Babin v. Pfizer, Inc., C.A. No. 2:05-1208

Deborah Ann Woodberry v. Pfizer, Inc., C.A. No. 2:05-1350

Terry Bridges v. Pfizer, Inc., C.A. No. 2:05-1353

George Hoffman v. Pfizer, Inc., C.A. No. 2:05-1354

Helen Anne Todini v. Pfizer, Inc., C.A. No. 2:05-1367

Betty A. Alexander, et al. v. Pfizer, Inc., C.A. No. 2:05-1720

Middle District of Louisiana

Ronald W. Abel, etc. v. Pfizer, Inc., C.A. No. 3:05-258

Western District of Louisiana

William Doss Turner v. Pfizer, Inc., C.A. No. 1:05-619

Yvonne Clark v. Pfizer, Inc., C.A. No. 1:05-620

District of Massachusetts

Health Care for All, et al. v. Pfizer, Inc., et al., C.A. No. 1:05-10707

Eastern District of Michigan

Linda A. Watters, et al. v. Pfizer, Inc., et al., C.A. No. 2:05-71434

District of Minnesota

Loretta M. Harris v. Pfizer, Inc., C.A. No. 0:05-728

Eastern District of New York

Melissa Kelly, et al. v. Pfizer, Inc., C.A. No. 1:05-949

Southern District of New York

ASEAJAFSCME Local 52 Health Benefits Trust v. Pfizer, Inc., et al., C.A. No. 1:05-3803

Steamfitters’ Industry Welfare Fund, et al. v. Pfizer, Inc., et al., C.A. No. 1:05-3814

Sheet Metal Workers’ International Assn. v. Pfizer, Inc., et al., C.A. No. 1:05-4125

Northern District of Ohio

Theresa Blatnik, et al. v. Pfizer, Inc., C.A. No. 1:05-900

Southern District of Texas

Ronald L. Baker, et al. v. Pfizer, Inc., C.A. No. 3:05-206 
      
      . At the hearing session in these four dockets, the Panel heard combined oral argument. Accordingly, the overlapping issues raised in these dockets are addressed in this one order.
      The Panel has been notified of more than 100 potentially related actions pending in multiple federal districts. In light of the Panel’s disposition of these dockets, the additional actions will be treated as potential tag-along actions. See Rules 7.4 and 7.5, R.P.J.P.M.L., 199 F.R.D. 425, 435-36 (2001).
     
      
      . One additional action, James Booker v. Merck & Co., Inc., et al., N.D. Texas, C.A. No. 3:05-496, was included on the MDL-1691 and MDL-1699 motions. The Panel's decision regarding inclusion of this action in mul-tidistrict proceedings will be addressed in a separate order.
     